GlassScriptPhysician profile
Maya Filipovic
NPI 1306222062
$1,690.28
in general payments reported to CMS, 2019-2025
10 companies · $325 in 2025
The $325 reported for 2025 was more than what 87% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.79 · 2023: $560 · 2024: $740 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $464.50 | 2024-2025 | Andexxa |
| Teleflex LLC | $334.61 | 2024-2025 | Arrow |
| Fisher & Paykel Healthcare INC | $250.99 | 2023 | Fisher & Paykel Healthcare |
| Access Vascular INC | $187.61 | 2024 | Hydromid Maximal Barrier Kit, Hydropicc Dual Lumen, Hydropicc Full Kit |
| Sobi, INC | $122.06 | 2023 | |
| Kci USA, INC. | $120.43 | 2023 | Tegaderm |
| Janssen Biotech, INC. | $66.27 | 2023 | Erleada |
| Masimo Corporation | $65.79 | 2022 | |
| Solventum Corporation | $58.72 | 2024 | Prevena |
| Janssen Pharmaceuticals, INC | $19.30 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Filipovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.